N Nora Bennani
Overview
Explore the profile of N Nora Bennani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Acosta-Medina A, Abeykoon J, Zanwar S, Ruan G, Rech K, Ravindran A, et al.
Leukemia
. 2025 Feb;
PMID: 39934281
No abstract available.
2.
Banks S, Decker P, Flanagan E, Zekeridou A, Go R, Abeykoon J, et al.
Blood Cancer J
. 2024 Sep;
14(1):153.
PMID: 39237493
No abstract available.
3.
Khurana A, Rosenthal A, Mohty R, Gaddam M, Bansal R, Hathcock M, et al.
Blood Cancer J
. 2024 Aug;
14(1):136.
PMID: 39134524
No abstract available.
4.
Jain M, Spiegel J, Nastoupil L, Tamaresis J, Ghobadi A, Lin Y, et al.
J Clin Oncol
. 2024 Aug;
42(30):3581-3592.
PMID: 39094076
Purpose: Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known...
5.
Nathoo N, Uhm J, Porter A, Hammack J, Jaeckle K, Mrugala M, et al.
Blood Cancer J
. 2024 Jun;
14(1):101.
PMID: 38902249
No abstract available.
6.
Bhansali R, Ellin F, Relander T, Cao M, Li W, Long Q, et al.
Blood Adv
. 2024 May;
8(13):3507-3518.
PMID: 38739715
Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS...
7.
Locke F, Siddiqi T, Jacobson C, Ghobadi A, Ahmed S, Miklos D, et al.
Blood
. 2024 Apr;
143(26):2722-2734.
PMID: 38635762
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by...
8.
Alhaj Moustafa M, Ramdial J, Tsalatsanis A, Khimani F, Dholaria B, Bojanini L, et al.
Transplant Cell Ther
. 2024 Mar;
30(5):516.e1-516.e10.
PMID: 38431075
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive type of peripheral T-cell lymphoma with median overall survival (OS) of approximately 1 year. Data on the effectiveness of hematopoietic cell...
9.
Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis
Ruan G, Zanwar S, Ravindran A, Schram S, Abeykoon J, Hazim A, et al.
Am J Hematol
. 2024 Feb;
99(5):871-879.
PMID: 38409747
Malignant histiocytosis (MH) is an extremely rare neoplasm of the macrophage-dendritic cell lineage. We report the clinical characteristics, molecular aberrations, treatments, and outcomes of patients with MH seen at two...
10.
Bansal R, Vergidis P, Tosh P, Wilson J, Hathcock M, Khurana A, et al.
Transplant Cell Ther
. 2024 Feb;
30(4):455.e1-455.e7.
PMID: 38346643
Antibody titers and the potential need for immunization have not been formally studied in recipients of chimeric antigen receptor T cell therapy (CAR-T). Prior studies have shown that CD19-targeted CAR-T...